Lineage Cell Therapeutics, Inc. (LCTX) › Weighted Average Diluted SharesLineage Cell Therapeutics, Inc. (LCTX) — Weighted Average Diluted SharesAnnual figures by period end, from SEC filings.2014-12-31: 66.47M2015-12-31: 79.71M2016-12-31: 99.55M2017-12-31: 114.48M2022-12-31: 169.79M2023-12-31: 172.66M2024-12-31: 200.19M2025-12-31: 230.12M230.12M2014-12-31Weighted Average Diluted Shares (shares)2025-12-31Period endedWeighted Average Diluted SharesChange YoYSource filing2025-12-31230.12M+14.9%2026-03-05From 2025-01-012024-12-31200.19M+15.9%2026-03-05From 2024-01-012023-12-31172.66M+1.7%2025-03-10From 2023-01-012022-12-31169.79M—2024-03-07From 2022-01-012017-12-31114.48M+15.0%2018-03-15From 2017-01-012016-12-3199.55M+24.9%2018-03-15From 2016-01-012015-12-3179.71M+19.9%2018-03-15From 2015-01-012014-12-3166.47M—2017-03-16From 2014-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareEPS (Basic)